IBL will develop biomarker panels for use with Grifols' random-access, single-molecule counting platform, and the firms will collaborate on testing workflows.

The assays measure phosphorylated tau 181 and apolipoprotein 4 to rule out whether a patient has Alzheimer's disease.

The aggregate repurchase authorization program now totals $200 million, which the firm will fund with cash and cash equivalents.

NEW YORK – With the launch of its first product, a rule-out test for pancreatic cysts that can help risk-stratify patients who may have pancreatic cancer, Purdue University spinout Amplified Sciences ...

The firm said that investors provided better-than-expected backing as the company anticipates growing use of its digital pathology platform in 2025.

The automated DxC 500 I analyzer has a throughput of up to 800 clinical chemistry tests and 100 immunoassays per hour.

The Switzerland-based firm's MosaiQ AiPlex Connective Tissue Diseases (CTDplus) assay is used to aid the diagnosis of autoimmune diseases.

The company presented its results this week at a conference and anticipates that with additional validation early next year, it will be ready to file for regulatory approval.

The purchase includes the manufacturing process of four ELISA kits, two of which are in vitro diagnostic products for specialty diagnostics and disease monitoring.

The firm's Innovance Antithrombin assay is used to monitor antithrombin activity levels in hemophilia patients and aid dosing decisions for a routine prophylaxis.

The firm's next-generation pancreatic cancer test looks for five biomarkers that are indicative of early-stage disease.

Of the 30 companies, three saw their stock prices increase, 26 saw their share prices decline, and one company's share price remained virtually flat month over month.